We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Surges on Regulatory Relief, Medicare Advantage Push: Time to Buy?
Read MoreHide Full Article
Key Takeaways
CVS stock has jumped 53.7% in 2025 on strong operations and a friendlier regulatory landscape.
Removal of PBM and Medicare Advantage cuts boosts CVS' Caremark and Aetna business lines.
CVS' digital care push, cost savings and expanded access are reinforcing its 2025 growth trajectory.
CVS Health (CVS - Free Report) has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance and a favorable regulatory outlook. The company raised its full-year 2025 EPS guidance on the first-quarter 2025 earnings call, which reflected solid execution across all business segments. Management emphasized a renewed focus on operational excellence, with a bolstered leadership team and a commitment to transforming healthcare delivery through digital innovation, affordability and improved access.
At the same time, external tailwinds such as the removal of proposed Medicare Advantage and PBM limitations from the Senate tax bill have lifted investor sentiment, reducing near-term policy risk for CVS’ core businesses. Together, these factors are reinforcing investor confidence and propelling CVS Health’s momentum in 2025.
Year to date, the stock has outperformed the broader Medical sector, the S&P 500 and its direct competitors, Herbalife Ltd (HLF - Free Report) and Walgreens Boots (WBA - Free Report) . While HLF and WBA gained 17.7% and 22.1%, respectively, during this period, the S&P 500 rose 1.8%. The Medical sector, in contrast, has declined 1.6% year to date.
YTD Price Comparison
Image Source: Zacks Investment Research
CVS Health to Benefit From Senate's Removal of PBM and Medicare Advantage Cuts
CVS Health is poised to benefit from the Senate’s latest tax bill revisions, which exclude proposed limits on Pharmacy Benefit Managers (PBMs) and cuts to Medicare Advantage programs.
Through its Caremark division, CVS operates one of the nation’s largest PBMs, managing drug benefits for millions of Americans. The Senate's move to strip proposed PBM constraints removes a significant regulatory overhang that could have impacted pricing power, rebate negotiations and margins. As noted in CVS Health’s Q1 2025 earnings release, Caremark delivered stable performance despite industry headwinds, driven by disciplined formulary management and client retention. The legislative reprieve provides additional room for CVS to scale its value-based pharmacy services and negotiate more effectively on behalf of plan sponsors.
Additionally, the Senate Finance Committee’s confirmation that Medicare Advantage cuts have been dropped is particularly beneficial for CVS Health’s insurance arm, Aetna, which has aggressively expanded its Medicare Advantage footprint. In recent earnings calls, CVS emphasized ongoing membership growth in Medicare Advantage. Preserving full federal funding ensures revenue stability and supports continued investment in member-centric services, such as in-home assessments and care coordination.
Another Key Takeaway
Streamlining Access and Lowering Costs: CVS Health is making care easier and faster by streamlining prior authorizations, with 95% of Aetna’s prior authorization requests now processed within 24 hours. Its bundled cancer care model is cutting delays and easing provider burden, with plans to expand to cardiology and musculoskeletal care.
Meanwhile, its pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence, especially among Medicare Advantage members. Strategic investments in technology and cost efficiency are fueling this performance.
On the affordability front, CVS is expanding access to critical therapies. It partnered with Novo Nordisk to offer Wegovy at lower costs through its weight management program and leads the U.S. market with its low-cost Humira biosimilar, Cordavis, generating over $1 billion in savings for clients.
CVS Health Offers Relative Value Amid Mixed Peer Comparisons
In terms of valuation, CVS Health’s forward 12-month price-to-earnings (P/E) is 10.37X, a discount to the S&P 500’s 21.86X.
Image Source: Zacks Investment Research
However, the stock is trading at a premium to the company’s competitors — Walgreens Boots Alliance’s average of 7.63X and Herbalife’s 3.77X.
CVS stock’s premium over peers may be justified by its scale, efficiency and strategic focus on digital health, AI and value-based care. Meanwhile, its discount to the S&P 500 offers an attractive entry point for long-term investors seeking stable, growth-oriented healthcare exposure.
CVS Health - A Buy Now
CVS Health's strong year-to-date stock performance, improved operational outlook and favorable regulatory environment make it an appealing investment opportunity in 2025. With a diversified business model spanning pharmacy services and insurance through Aetna, CVS is well-positioned to capitalize on long-term healthcare trends. The company’s cost-control measures, digital transformation efforts and initiatives to improve care access and affordability are reinforcing investor confidence. This Zacks Rank #2 (Buy) stock holds potential for continued upside momentum on regulatory relief, courtesy of the proposed removal of PBM and Medicare Advantage cuts. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
CVS Surges on Regulatory Relief, Medicare Advantage Push: Time to Buy?
Key Takeaways
CVS Health (CVS - Free Report) has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance and a favorable regulatory outlook. The company raised its full-year 2025 EPS guidance on the first-quarter 2025 earnings call, which reflected solid execution across all business segments. Management emphasized a renewed focus on operational excellence, with a bolstered leadership team and a commitment to transforming healthcare delivery through digital innovation, affordability and improved access.
At the same time, external tailwinds such as the removal of proposed Medicare Advantage and PBM limitations from the Senate tax bill have lifted investor sentiment, reducing near-term policy risk for CVS’ core businesses. Together, these factors are reinforcing investor confidence and propelling CVS Health’s momentum in 2025.
Year to date, the stock has outperformed the broader Medical sector, the S&P 500 and its direct competitors, Herbalife Ltd (HLF - Free Report) and Walgreens Boots (WBA - Free Report) . While HLF and WBA gained 17.7% and 22.1%, respectively, during this period, the S&P 500 rose 1.8%. The Medical sector, in contrast, has declined 1.6% year to date.
YTD Price Comparison
Image Source: Zacks Investment Research
CVS Health to Benefit From Senate's Removal of PBM and Medicare Advantage Cuts
CVS Health is poised to benefit from the Senate’s latest tax bill revisions, which exclude proposed limits on Pharmacy Benefit Managers (PBMs) and cuts to Medicare Advantage programs.
Through its Caremark division, CVS operates one of the nation’s largest PBMs, managing drug benefits for millions of Americans. The Senate's move to strip proposed PBM constraints removes a significant regulatory overhang that could have impacted pricing power, rebate negotiations and margins. As noted in CVS Health’s Q1 2025 earnings release, Caremark delivered stable performance despite industry headwinds, driven by disciplined formulary management and client retention. The legislative reprieve provides additional room for CVS to scale its value-based pharmacy services and negotiate more effectively on behalf of plan sponsors.
Additionally, the Senate Finance Committee’s confirmation that Medicare Advantage cuts have been dropped is particularly beneficial for CVS Health’s insurance arm, Aetna, which has aggressively expanded its Medicare Advantage footprint. In recent earnings calls, CVS emphasized ongoing membership growth in Medicare Advantage. Preserving full federal funding ensures revenue stability and supports continued investment in member-centric services, such as in-home assessments and care coordination.
Another Key Takeaway
Streamlining Access and Lowering Costs: CVS Health is making care easier and faster by streamlining prior authorizations, with 95% of Aetna’s prior authorization requests now processed within 24 hours. Its bundled cancer care model is cutting delays and easing provider burden, with plans to expand to cardiology and musculoskeletal care.
Meanwhile, its pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence, especially among Medicare Advantage members. Strategic investments in technology and cost efficiency are fueling this performance.
On the affordability front, CVS is expanding access to critical therapies. It partnered with Novo Nordisk to offer Wegovy at lower costs through its weight management program and leads the U.S. market with its low-cost Humira biosimilar, Cordavis, generating over $1 billion in savings for clients.
CVS Health Offers Relative Value Amid Mixed Peer Comparisons
In terms of valuation, CVS Health’s forward 12-month price-to-earnings (P/E) is 10.37X, a discount to the S&P 500’s 21.86X.
Image Source: Zacks Investment Research
However, the stock is trading at a premium to the company’s competitors — Walgreens Boots Alliance’s average of 7.63X and Herbalife’s 3.77X.
CVS stock’s premium over peers may be justified by its scale, efficiency and strategic focus on digital health, AI and value-based care. Meanwhile, its discount to the S&P 500 offers an attractive entry point for long-term investors seeking stable, growth-oriented healthcare exposure.
CVS Health - A Buy Now
CVS Health's strong year-to-date stock performance, improved operational outlook and favorable regulatory environment make it an appealing investment opportunity in 2025. With a diversified business model spanning pharmacy services and insurance through Aetna, CVS is well-positioned to capitalize on long-term healthcare trends. The company’s cost-control measures, digital transformation efforts and initiatives to improve care access and affordability are reinforcing investor confidence. This Zacks Rank #2 (Buy) stock holds potential for continued upside momentum on regulatory relief, courtesy of the proposed removal of PBM and Medicare Advantage cuts. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.